FDA
-
-
-
-
-
-
-
Lyra Therapeutics (LYRA) PT Raised to $16 at H.C. Wainwright
-
-
-
-
-
-
-
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
-
-
-
-
-
-
-
Lyra Therapeutics (LYRA) Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220
-
-
-
-
-
-
-
Lyra Therapeutics (LYRA) Restarts Phase 3 ENLIGHTEN II Clinical Trial of LYR-210
-
-
-
-
-
-
-
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022
-
-
-
-
-
-
-
Lyra Therapeutics to Present at Upcoming Investor Conferences
-
322,088 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

